Illumina

ILMN

Market cap $22B

Illumina, Inc. (ILMN) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

Gene sequencing company Illumina on Tuesday introduced a dataset that maps genetic changes to help accelerate drug discovery through artificial intelligence.

The Atlas will enable the validation of genetic targets and training of AI models at unprecedented scale SAN DIEGO, Jan. 13, 2026 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN) today introduced the world's largest genome-wide genetic perturbation dataset, being built to accelerate drug discovery through AI across the pharmaceutical ecosystem. The Illumina Billion Cell Atlas is the first tranche of its program to build a 5 billion cell atlas over three years, and will be the most comprehensive map of human disease biology to date.

SAN DIEGO, Jan. 13, 2026 /PRNewswire/ -- Illumina, Inc. (Nasdaq: ILMN) ("Illumina" or the "company") today announced unaudited preliminary financial results for the fourth quarter and fiscal year 2025 ahead of its presentation at the 44th Annual J.P. Morgan Healthcare Conference on January 13, 2026 at 7:30 a.m.

SAN DIEGO, Jan. 12, 2026 /PRNewswire/ -- Illumina, Inc. (NASDAQ:ILMN) announced today that it will issue results for the fourth quarter and full year 2025 following the close of market on Thursday, February 5, 2026. On the same day, at 1:30 pm Pacific Time (4:30 pm Eastern Time) Jacob Thaysen, PhD, Chief Executive Officer, and Ankur Dhingra, Chief Financial Officer, will host a conference call with analysts, investors, and other interested parties to discuss financial and operating results.

ILMN's Connected Multiomics, launched after early user input, advances precision health research and may boost the stock.

Illumina (ILMN) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Veteran genomics leader joins Illumina to advance global medical strategy Illumina chief commercial officer to depart for role as a life science tools company CEO  SAN DIEGO, Jan. 8, 2026 /PRNewswire/ -- Today, Illumina, Inc. (NASDAQ: ILMN) announced the appointment of Eric D. Green, M.D.

TAIPEI, Taiwan, Jan. 08, 2026 (GLOBE NEWSWIRE) -- Illumina Taiwan Biotechnology Co., Ltd., and Precision Medicine Asia, Limited (PREMIA), a leading Asian cancer clinical-genomic screening network, today announced the formation of a strategic partnership that will expand access to comprehensive genomic profiling (CGP) for all eligible oncology patients across the Chang Gung Memorial Hospital (CGMH) system. This partnership also aims to support the creation of an Asia-wide clinical-genomic oncology database to advance precision oncology.

Investors interested in stocks from the Medical - Biomedical and Genetics sector have probably already heard of Regeneron (REGN) and Illumina (ILMN). But which of these two stocks offers value investors a better bang for their buck right now?